Update sample_questions.json

Rename `clinical_info` to `clinical_context`

sample_questions.json

@@ -11,7 +11,7 @@
           "zygosity": "hemizygous"
         }
       ],
-      "clinical_info": "Progressive muscle weakness"
+      "clinical_context": "Progressive muscle weakness"
     },
     "question": "To which of the following targeted therapies would this variant be most likely amenable: Golodirsen, Viltolarsen, Eteplirsen, Casimersen, Ataluren, or None?",
     "answer": "Eteplirsen",
@@ -32,7 +32,7 @@
           "zygosity": "hemizygous"
         }
       ],
-      "clinical_info": "Progressive muscle weakness"
+      "clinical_context": "Progressive muscle weakness"
     },
     "question": "To which of the following targeted therapies would this variant be most likely amenable: Golodirsen, Viltolarsen, Eteplirsen, Casimersen, Ataluren, or None?",
     "answer": "Ataluren",
@@ -53,7 +53,7 @@
           "zygosity": "hemizygous"
         }
       ],
-      "clinical_info": "Progressive muscle weakness"
+      "clinical_context": "Progressive muscle weakness"
     },
     "question": "To which of the following targeted therapies would this variant be most likely amenable: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Ataluren, or None?",
     "answer": "None",
@@ -74,7 +74,7 @@
           "zygosity": "homozygous"
         }
       ],
-      "clinical_info": "Recurrent nephrocalcinosis and chronic kidney disease"
+      "clinical_context": "Recurrent nephrocalcinosis and chronic kidney disease"
     },
     "question": "What targeted, small molecule therapy is available for this patient? Provide the generic name or None.",
     "answer": "Pyridoxine",
@@ -95,7 +95,7 @@
           "zygosity": "homozygous"
         }
       ],
-      "clinical_info": "Recurrent nephrocalcinosis and chronic kidney disease"
+      "clinical_context": "Recurrent nephrocalcinosis and chronic kidney disease"
     },
     "question": "Is this patient predicted to be responsive to pyridoxine? Answer yes or no.",
     "answer": "No",
@@ -116,7 +116,7 @@
           "zygosity": "homozygous"
         }
       ],
-      "clinical_info": "7 year old with recurrent nephrocalcinosis and chronic kidney disease"
+      "clinical_context": "7 year old with recurrent nephrocalcinosis and chronic kidney disease"
     },
     "question": "What targeted, genetic therapies are approved for this patient in the US? Provide the generic name.",
     "answer": "Lumasiran",
@@ -137,7 +137,7 @@
           "zygosity": "homozygous"
         }
       ],
-      "clinical_info": "Global developmental delay"
+      "clinical_context": "Global developmental delay"
     },
     "question": "What is the youngest age for which a gene therapy is approved for this patient's genetic condition in the united kingdom? Answer with the format \"X months\".",
     "answer": "18 months",
@@ -158,7 +158,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "joint hypermobility, skin hyperextensibility, and easy bruising"
+      "clinical_context": "joint hypermobility, skin hyperextensibility, and easy bruising"
     },
     "question": "What two medications are most established for decreasing bruising? List generic names in alphabetical order",
     "answer": "ascorbic acid, desmopressin",
@@ -179,7 +179,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "Patient with SLC35A2-CDG who is experiencing seizures and global developmental delay"
+      "clinical_context": "Patient with SLC35A2-CDG who is experiencing seizures and global developmental delay"
     },
     "question": "What clinical trial developing a new therapeutic for this condition is recruiting or listed as upcoming/not yet recruiting? Return a clinical trials ID",
     "answer": "NCT05402384",
@@ -200,7 +200,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "seizures and global developmental delay. Age 2 months, Hemoglobin 5, Normal liver labs, Not enrolled in other trials"
+      "clinical_context": "seizures and global developmental delay. Age 2 months, Hemoglobin 5, Normal liver labs, Not enrolled in other trials"
     },
     "question": "Is this patient eligible for clinical trial NCT05402384? Answer yes or no.",
     "answer": "No",
@@ -221,7 +221,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "early-onset seizures and developmental delays"
+      "clinical_context": "early-onset seizures and developmental delays"
     },
     "question": "For which clinical trials evaluating new therapeutics is this patient eligible? Provide a clinical trial ID or answer None.",
     "answer": "None",
@@ -242,7 +242,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "intellectual disability, seizures, and developmental delays"
+      "clinical_context": "intellectual disability, seizures, and developmental delays"
     },
     "question": "Is it more likely amenable to treatment with Memantine, L-serine, or Radiprodil",
     "answer": "L-Serine",
@@ -263,7 +263,7 @@
           "zygosity": "homozygous"
         }
       ],
-      "clinical_info": "progressive cerebellar ataxia and peripheral neuropathy"
+      "clinical_context": "progressive cerebellar ataxia and peripheral neuropathy"
     },
     "question": "How many amino acids are coded for by the exon in which this variant occurs? Answer with a number",
     "answer": "66",
@@ -284,7 +284,7 @@
           "zygosity": "homozygous"
         }
       ],
-      "clinical_info": "progressive cerebellar ataxia and peripheral neuropathy"
+      "clinical_context": "progressive cerebellar ataxia and peripheral neuropathy"
     },
     "question": "What percentage of the total coding transcript for this gene are encoded by the exon in which this variant occurs? Answer with a decimal to nearest tenth.",
     "answer": "0.1",
@@ -305,7 +305,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "childhood-onset generalized dystonia"
+      "clinical_context": "childhood-onset generalized dystonia"
     },
     "question": "Based on typical prediction rules, is this variant likely to result in nonsense mediated decay? Answer yes or no.",
     "answer": "No",
@@ -326,7 +326,7 @@
           "zygosity": "heterozygous"
         }
       ],
-      "clinical_info": "Malignant Peripheral Nerve Sheath Tumor and Pheochromocytoma"
+      "clinical_context": "Malignant Peripheral Nerve Sheath Tumor and Pheochromocytoma"
     },
     "question": "In which functional domain does this variant occur? Answer choices: CSRD, TBD, GRD, Sec14-PH, HLR, NLS, SBR.",
     "answer": "GRD",